Indivior's Research on Opioid Treatment Shows Promising Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 20 2026
0mins
Source: Newsfilter
Indivior Pharmaceuticals, Inc. has seen its stock price rise by 12.94% as it reaches a 52-week high.
The company showcased collaborative research with Virginia Tech at a recent conference, highlighting the effectiveness of its extended-release buprenorphine product, SUBLOCADE®, in improving the quality of life for patients with opioid use disorder. The study revealed that patients receiving buprenorphine had significantly lower rates of both non-fatal and fatal overdose events, especially when treatment coverage exceeded 80%. This reinforces Indivior's leadership in the opioid treatment sector and its long-term commitment to advancing effective treatment strategies.
The implications of this research are significant, as they provide crucial evidence for clinical practices and emphasize the importance of remission indicators in treatment outcomes. Indivior's ongoing dedication to improving care for opioid use disorder patients positions it favorably in the market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INDV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INDV
Wall Street analysts forecast INDV stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 37.530
Low
36.00
Averages
43.75
High
50.00
Current: 37.530
Low
36.00
Averages
43.75
High
50.00
About INDV
Indivior Pharmaceuticals, Inc. is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. It sells its products in the United States and in other selected areas of the world.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Black Diamond Therapeutics Shares Plunge 35.8% Amid Mixed Phase II Results
- Clinical Trial Results: Black Diamond Therapeutics reported a preliminary median progression-free survival (mPFS) of 15.2 months for its phase II trial of silevertinib in NSCLC patients with EGFR non-classical mutations, yet the stock plummeted 35.8% as investors expressed concerns over the early nature of the data and modest patient count.
- Patient Data Analysis: The study enrolled 43 patients treated with a 200 mg dose of silevertinib, with 53% remaining on therapy at the data cutoff, and the longest treatment duration reaching 23.5 months, indicating potential durability of responses, although longer follow-up is needed to clarify the final benefit-risk profile.
- CNS Activity: Silevertinib demonstrated an 86% objective response rate in the central nervous system (CNS), with no new brain metastases reported by the cutoff date, suggesting this profile could be pivotal for the company's development and regulatory strategy, particularly if maintained in larger datasets.
- Safety Management: No new safety signals were observed, but severe treatment-related adverse events decreased to 28% after dose reduction, supporting the decision to adjust the dose to 150 mg; however, the need for dose optimization may have contributed to the negative market reaction.
See More
Indivior's New Data Significantly Reduces Relapse Risk
- Relapse Risk Reduction: A claims-based study involving 3,400 patients found that those adhering to monthly Buprenorphine injections were 3.5 to 8.1 times less likely to relapse, demonstrating the treatment's effectiveness in addressing opioid use disorder.
- Lower Healthcare Utilization: Compared to nearly 120,000 patients on daily oral Buprenorphine, 467 patients on monthly injections showed significant improvements in healthcare utilization, with bloodstream infections reduced by 62%, inpatient visits by 56%, and emergency and outpatient visits by 22% and 21%, respectively.
- Company Commentary: Indivior's CSO Christian Heidbreder emphasized that sustained monthly injection treatment not only reduces relapse risk but also lessens serious complications that drive acute care needs, thereby supporting long-term recovery.
- Strategic Outlook: Funded by Indivior and conducted with academic partners, these studies highlight the importance of SUBLOCADE as part of a comprehensive treatment plan, indicating that combining it with psychological support can further enhance treatment outcomes.
See More
Claret Asset Management Acquires Indivior Shares Worth $23.36 Million
- New Investment Position: Claret Asset Management established a new position in Indivior during Q1 2026 by acquiring 707,267 shares valued at $23.36 million, indicating strong confidence in the company's growth potential.
- Holding Value Fluctuation: By the end of the quarter, Claret's holding in Indivior was valued at $21.56 million, reflecting market price changes and adjustments in asset allocation post-acquisition, thereby enhancing portfolio diversity.
- Significant Performance Growth: Indivior reported a 19% year-over-year revenue increase to $317 million in Q1, with Sublocade sales surging 32% to $232 million, demonstrating robust market demand for opioid dependence treatments.
- Strategic Buybacks: Indivior repurchased approximately 4 million shares for $125 million during the quarter and announced a $175 million accelerated share repurchase agreement with Barclays, reflecting confidence in its stock price and future growth expectations.
See More
Indivior Enters $175M Accelerated Share Repurchase Agreement with Barclays
- Repurchase Agreement Details: Indivior has entered into a $175M accelerated share repurchase agreement with Barclays, expecting an initial delivery of 3,717,473 shares, reflecting the company's confidence in its stock value.
- Funding Arrangement: This repurchase will be executed under Indivior's existing $400M share repurchase program, indicating a proactive strategy in capital management aimed at enhancing shareholder returns.
- Financial Impact: Indivior does not expect this repurchase to affect its previously issued financial guidance, demonstrating the company's commitment to maintaining financial stability.
- Future Repurchase Potential: Following this repurchase, Indivior retains an additional $100M under its repurchase authorization, allowing for further buybacks based on market conditions, which could further bolster shareholder confidence.
See More
Indivior Announces $175 Million Accelerated Share Repurchase Agreement
- Repurchase Agreement Details: Indivior Pharmaceuticals has signed a $175 million accelerated share repurchase agreement with Barclays, part of its $400 million buyback program, with final settlement expected by the end of June, reflecting the company's confidence in its long-term strategy.
- Initial Delivery Quantity: The company will make an upfront payment of $175 million and expects an initial delivery of approximately 3.72 million shares, with the final number of shares repurchased based on the volume-weighted average price during the agreement term, ensuring flexibility and market adaptability in the buyback process.
- Remaining Buyback Funds: Following this agreement, Indivior has an additional $100 million under its share repurchase authorization for further buybacks, indicating a proactive approach to capital management aimed at enhancing shareholder value.
- Market Reaction: In pre-market trading on Nasdaq, Indivior shares rose by 3.27% to $38.89, reflecting a positive market response to the company's buyback plan, which may further bolster investor confidence.
See More
Indivior Collaborates with Virginia Tech on Opioid Use Disorder Research
- Research Presentation: Indivior showcased collaborative research with Virginia Tech at the American Society of Addiction Medicine annual conference, highlighting the efficacy of extended-release buprenorphine (SUBLOCADE®) in improving quality of life and reducing overdose risks for opioid use disorder patients, thereby reinforcing its leadership in the opioid treatment sector.
- Reduced Overdose Risk: The study indicates that patients treated with buprenorphine had the lowest proportions of non-fatal and fatal overdose events, particularly when treatment coverage exceeded 80%, providing crucial evidence for clinical practice regarding effective treatment strategies.
- Importance of Remission Indicators: In a study involving 443 participants, those entering remission showed better outcomes in terms of reduced cravings, withdrawal symptoms, and improved quality of life, emphasizing the significance of remission as a treatment endpoint beyond mere abstinence criteria.
- Long-term Commitment: Indivior's Chief Scientific Officer stated that for 25 years, the company has been dedicated to advancing science that improves care for opioid use disorder patients, demonstrating ongoing efforts to promote effective treatment and expand access to quality care.
See More
Black Diamond Therapeutics Shares Plunge 35.8% Amid Mixed Phase II Results
- Clinical Trial Results: Black Diamond Therapeutics reported a preliminary median progression-free survival (mPFS) of 15.2 months for its phase II trial of silevertinib in NSCLC patients with EGFR non-classical mutations, yet the stock plummeted 35.8% as investors expressed concerns over the early nature of the data and modest patient count.
- Patient Data Analysis: The study enrolled 43 patients treated with a 200 mg dose of silevertinib, with 53% remaining on therapy at the data cutoff, and the longest treatment duration reaching 23.5 months, indicating potential durability of responses, although longer follow-up is needed to clarify the final benefit-risk profile.
- CNS Activity: Silevertinib demonstrated an 86% objective response rate in the central nervous system (CNS), with no new brain metastases reported by the cutoff date, suggesting this profile could be pivotal for the company's development and regulatory strategy, particularly if maintained in larger datasets.
- Safety Management: No new safety signals were observed, but severe treatment-related adverse events decreased to 28% after dose reduction, supporting the decision to adjust the dose to 150 mg; however, the need for dose optimization may have contributed to the negative market reaction.
See More
Indivior's New Data Significantly Reduces Relapse Risk
- Relapse Risk Reduction: A claims-based study involving 3,400 patients found that those adhering to monthly Buprenorphine injections were 3.5 to 8.1 times less likely to relapse, demonstrating the treatment's effectiveness in addressing opioid use disorder.
- Lower Healthcare Utilization: Compared to nearly 120,000 patients on daily oral Buprenorphine, 467 patients on monthly injections showed significant improvements in healthcare utilization, with bloodstream infections reduced by 62%, inpatient visits by 56%, and emergency and outpatient visits by 22% and 21%, respectively.
- Company Commentary: Indivior's CSO Christian Heidbreder emphasized that sustained monthly injection treatment not only reduces relapse risk but also lessens serious complications that drive acute care needs, thereby supporting long-term recovery.
- Strategic Outlook: Funded by Indivior and conducted with academic partners, these studies highlight the importance of SUBLOCADE as part of a comprehensive treatment plan, indicating that combining it with psychological support can further enhance treatment outcomes.
See More
Claret Asset Management Acquires Indivior Shares Worth $23.36 Million
- New Investment Position: Claret Asset Management established a new position in Indivior during Q1 2026 by acquiring 707,267 shares valued at $23.36 million, indicating strong confidence in the company's growth potential.
- Holding Value Fluctuation: By the end of the quarter, Claret's holding in Indivior was valued at $21.56 million, reflecting market price changes and adjustments in asset allocation post-acquisition, thereby enhancing portfolio diversity.
- Significant Performance Growth: Indivior reported a 19% year-over-year revenue increase to $317 million in Q1, with Sublocade sales surging 32% to $232 million, demonstrating robust market demand for opioid dependence treatments.
- Strategic Buybacks: Indivior repurchased approximately 4 million shares for $125 million during the quarter and announced a $175 million accelerated share repurchase agreement with Barclays, reflecting confidence in its stock price and future growth expectations.
See More
Indivior Enters $175M Accelerated Share Repurchase Agreement with Barclays
- Repurchase Agreement Details: Indivior has entered into a $175M accelerated share repurchase agreement with Barclays, expecting an initial delivery of 3,717,473 shares, reflecting the company's confidence in its stock value.
- Funding Arrangement: This repurchase will be executed under Indivior's existing $400M share repurchase program, indicating a proactive strategy in capital management aimed at enhancing shareholder returns.
- Financial Impact: Indivior does not expect this repurchase to affect its previously issued financial guidance, demonstrating the company's commitment to maintaining financial stability.
- Future Repurchase Potential: Following this repurchase, Indivior retains an additional $100M under its repurchase authorization, allowing for further buybacks based on market conditions, which could further bolster shareholder confidence.
See More
Indivior Announces $175 Million Accelerated Share Repurchase Agreement
- Repurchase Agreement Details: Indivior Pharmaceuticals has signed a $175 million accelerated share repurchase agreement with Barclays, part of its $400 million buyback program, with final settlement expected by the end of June, reflecting the company's confidence in its long-term strategy.
- Initial Delivery Quantity: The company will make an upfront payment of $175 million and expects an initial delivery of approximately 3.72 million shares, with the final number of shares repurchased based on the volume-weighted average price during the agreement term, ensuring flexibility and market adaptability in the buyback process.
- Remaining Buyback Funds: Following this agreement, Indivior has an additional $100 million under its share repurchase authorization for further buybacks, indicating a proactive approach to capital management aimed at enhancing shareholder value.
- Market Reaction: In pre-market trading on Nasdaq, Indivior shares rose by 3.27% to $38.89, reflecting a positive market response to the company's buyback plan, which may further bolster investor confidence.
See More
Indivior Collaborates with Virginia Tech on Opioid Use Disorder Research
- Research Presentation: Indivior showcased collaborative research with Virginia Tech at the American Society of Addiction Medicine annual conference, highlighting the efficacy of extended-release buprenorphine (SUBLOCADE®) in improving quality of life and reducing overdose risks for opioid use disorder patients, thereby reinforcing its leadership in the opioid treatment sector.
- Reduced Overdose Risk: The study indicates that patients treated with buprenorphine had the lowest proportions of non-fatal and fatal overdose events, particularly when treatment coverage exceeded 80%, providing crucial evidence for clinical practice regarding effective treatment strategies.
- Importance of Remission Indicators: In a study involving 443 participants, those entering remission showed better outcomes in terms of reduced cravings, withdrawal symptoms, and improved quality of life, emphasizing the significance of remission as a treatment endpoint beyond mere abstinence criteria.
- Long-term Commitment: Indivior's Chief Scientific Officer stated that for 25 years, the company has been dedicated to advancing science that improves care for opioid use disorder patients, demonstrating ongoing efforts to promote effective treatment and expand access to quality care.
See More
